The present invention relates to peptides and compositions for use in improving transduction efficiency of viruses into target cells.

Disclosed herein is a fusion protein for gene editing, comprising a Cas9 domain that is configured to be encapsulated into exosomes and to localize to the nucleus of recipient cells. Also disclosed are recombinant polynucleotides that comprise a nucleic acid sequence encoding the disclosed Cas9 fusion protein. Also disclosed are cells comprising the disclosed polynucleotides. Also disclosed are methods of making a gene editing composition that involve culturing the disclosed cells under conditions suitable to produce extracellular vesicles encapsulating the guide RNA and fusion protein. Also disclosed are gene editing compositions that involve extracellular vesicles encapsulating the disclosed Cas9 fusion proteins and guide RNA. Finally, also disclosed herein are methods for editing a gene in a cell that involves contact the cell with the herein disclosed gene editing compositions.

Fusion molecules of a cytokine or portion thereof and a polypeptide which targets the fusion protein to phosphatidylserine, pharmaceutical compositions thereof, and methods for their use in targeting a cytokine or portion thereof to a pathological site and treating a disease or condition responsive to cytokine treatment are provided.

The present invention relates to a cell which comprises a chimeric antigen receptor (CAR) and a signal transduction modifying protein, selected from one of the following: (i) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM), but lacks a kinase domain; (ii) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM) but lacks a phosphatase domain; (iii) a fusion protein which comprises (a) an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM) or from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM); and (ii) a heterologous domain.

Chimeric antigen receptors for use in treating malignant melanoma and other cancers expressing CS1 are described.

A recombinant protein for use in a liquid culture medium for photo-autotrophic micropropagation of Cannabis sativa L. is disclosed. The recombinant protein comprises a fusion of a growth induction part and a uptake enhancement part. The growth induction part comprises an Arabinogalactan protein and/or a plant transcription factor associated with plant growth and development. The uptake enhancement part comprises a cell penetrating peptide sequence and a nuclear localization signal encoded by the peptide sequence SEQ ID NO 1.

The present disclosure concerns recombinant yeast host cells expressing cell-associated heterologous proteins which are expressed during the propagation phase of the recombinant yeast host cells and processes for propagating same. The recombinant yeast host cells can be 5 used to make a yeast composition or a yeast product enriched in the heterologous proteins.

The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.

Provided are ciliary neurotrophic factor receptor (CNTFR) ligands. In certain aspects, a CNTFR ligand of the present disclosure exhibits increased affinity for CNTFR relative to the corresponding wild-type CNTFR ligand. In certain aspects, a CNTFR ligand of the present disclosure results in reduced binding affinity of glycoprotein 130 (gp130), leukemia inhibitory factor receptor (LIFR), or both, for a complex including the CNTFR ligand and CNTFR, relative to the binding affinity for a complex including the corresponding wild-type CNTFR ligand and CNTFR. In certain aspects, a CNTFR ligand of the present disclosure has both of the aforementioned properties. Also provided are pharmaceutical compositions including the CNTFR ligands, as well as methods of using the CNTFR ligands.

Provided herein, in some embodiments, are antibodies, antigen-binding antibody fragments, chimeric antigen receptors (CARs) and bispecific T cell engagers (BiTEs) that bind specifically to 137 homolog 6. Also provided herein are methods of using the same and cells comprising the same.